CDL Research, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
CDL Research, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
Adv Drug Deliv Rev. 2024 Mar;206:115190. doi: 10.1016/j.addr.2024.115190. Epub 2024 Feb 1.
mRNA-based vaccines are emerging as a promising alternative to standard cancer treatments and the conventional vaccines. Moreover, the FDA-approval of three nucleic acid based therapeutics (Onpattro, BNT162b2 and mRNA-1273) has further increased the interest and trust on this type of therapeutics. In order to achieve a significant therapeutic efficacy, the mRNA needs from a drug delivery system. In the last years, several delivery platforms have been explored, being the lipid nanoparticles (LNPs) the most well characterized and studied. A better understanding on how mRNA-based therapeutics operate (both the mRNA itself and the drug delivery system) will help to further improve their efficacy and safety. In this review, we will provide an overview of what mRNA cancer vaccines are and their mode of action and we will highlight the advantages and challenges of the different delivery platforms that are under investigation.
mRNA 疫苗作为标准癌症治疗方法和传统疫苗的一种有前途的替代方法正在出现。此外，FDA 批准了三种基于核酸的治疗药物（Onpattro、BNT162b2 和 mRNA-1273），进一步提高了人们对这类治疗药物的兴趣和信任。为了实现显著的治疗效果，mRNA 需要药物输送系统。在过去的几年中，已经探索了几种输送平台，其中脂质纳米颗粒（LNPs）是最具代表性和研究最充分的。更好地了解基于 mRNA 的治疗药物的作用方式（包括 mRNA 本身和药物输送系统）将有助于进一步提高其疗效和安全性。在这篇综述中，我们将概述什么是 mRNA 癌症疫苗及其作用模式，并强调正在研究的不同输送平台的优势和挑战。
